Van Caekenberghe D
Department of Medical Microbiology, Military Hospital, Brussels, Belgium.
J Antimicrob Chemother. 1990 Sep;26(3):381-6. doi: 10.1093/jac/26.3.381.
The in-vitro activities of eight new quinolones (A-56620, amifloxacin, difloxacin, CI-934, enoxacin, irloxacin, pefloxacin, temafloxacin), two reference fluoroquinolones (ciprofloxacin and ofloxacin) and fusidic acid against 147 mycobacterial strains, belonging to seven different species, were compared. Temafloxacin, ofloxacin and ciprofloxacin were the most active compounds. They only showed consistent activity against Mycobacterium tuberculosis, M. malmoense and M. fortuitum, but not against M. chelonei, M. avium, M. intracellulare and M. scrofulaceum. However, individual strains of these species were sometimes susceptible. The best overall in-vitro activity was obtained with temafloxacin, which often showed activity where other products were inactive. Fusidic acid merely displayed good activity against M. tuberculosis (MIC90 16 mg/l).
比较了8种新型喹诺酮类药物(A-56620、阿米氟沙星、二氟沙星、CI-934、依诺沙星、伊洛沙星、培氟沙星、替马沙星)、2种氟喹诺酮类对照药物(环丙沙星和氧氟沙星)以及夫西地酸对属于7个不同菌种的147株分枝杆菌菌株的体外活性。替马沙星、氧氟沙星和环丙沙星是活性最强的化合物。它们仅对结核分枝杆菌、马尔默分枝杆菌和偶然分枝杆菌表现出持续活性,而对龟分枝杆菌、鸟分枝杆菌、胞内分枝杆菌和瘰疬分枝杆菌无活性。然而,这些菌种的个别菌株有时也敏感。替马沙星的总体体外活性最佳,在其他产品无活性的情况下它常常表现出活性。夫西地酸仅对结核分枝杆菌显示出良好活性(MIC90为16mg/l)。